Shares of SCHOTT Pharma jumped after Deutsche Bank elevated its recommendation on the company from Hold to Buy and raised its price objective to €22, up from €16. The upgrade, penned by analyst Falko Friedrichs, frames the change as a response to what the analyst sees as a reversal of a recent demand shock that had weighed on the group's first-half results.
Friedrichs' note points to a specific disruption in customer demand: a major client reduced orders for glass syringes, creating a temporary drag on both revenue and profitability in the first half. According to the analyst, that headwind is largely in the rearview mirror, and the company should see the acceleration that was deferred materialize in the third and fourth quarters.
The broker's revised thesis combines an expectation of meaningfully stronger growth with margin expansion in the second half of the fiscal year. Market participants reacted to the upgrade and higher target, with the stock trading at €17.32 at the time cited - a level that remains below Deutsche Bank's new target and the stock's 52-week high of €26.80, signaling scope for further re-rating if the analyst's outlook proves correct.
Broader market dynamics amplified the move. European equities were generally firmer on the session, with both Italy's FTSE MIB - the benchmark for Milan where SCHOTT Pharma also trades - and Germany's DAX in positive territory. The constructive macro backdrop, together with what the report described as easing concerns around European interest rate policy, helped to bolster the effect of the analyst action on sentiment.
In short, a substantive analyst upgrade that increased both rating and price target substantially, combined with a supportive market tone, produced the pronounced uptick in SCHOTT Pharma shares observed today. The reaction has refocused investor attention on a stock that had faced significant pressure over the prior year due to the temporary demand shortfall.
Summary
Deutsche Bank upgraded SCHOTT Pharma to Buy and raised its price target to €22 from €16, arguing the firm has moved past a demand trough caused by reduced glass syringe orders from a major customer and forecasting stronger H2 growth and margin improvement; the upgrade coincided with broadly positive European equity markets and easing rate concerns.